HOUSTON, TX—(Marketwired – April 24, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement to expand production capability for Annamycin.
Moleculin has engaged BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy to begin preparations for commercial scale production of Annamycin drug product.
“With the Phase I/II clinical trial of Annamycin now under way, we are taking the necessary steps to prepare for the commercial scale production of Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin. “BSP has a solid track record for supplying liposomal formulations to large pharmaceutical companies and their capabilities are a good match for us. We believe this partnership will assist us to take Annamycin to the next level.”
Mr. Aldo Braca, CEO of BSP Pharmaceuticals, added, “We see the potential for Annamycin to become a game–changer in the acute leukemia space, so we are pleased to be working with Moleculin.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno–stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com.
Some of the statements in this release are forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward–looking statements in this press release include, without limitation, the ability of Annamycin to reach commercial scale demand and production capability. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward–looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward–looking statements. Moleculin Biotech has attempted to identify forward–looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward–looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10–K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10–Q filings and in our other public filings with the SEC. Any forward–looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward–looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.